Xingyuan Xu

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 5

Top Topics

Polycyclic Aromatic Hydrocarbons

Combination Therapy

Prognostic Factors

Top Venues

Journal of immunology (Baltimore, Md. : 1950)

This page only lists publications with an associated author ORCID identifier.

Publications

Enliang Li, Jian Xu, Qi Chen, Xiaozhen Zhang, Xingyuan Xu, Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Immunotherapy 15 (3) (2023)
Enliang Li, Jian Xu, Qi Chen, Xiaozhen Zhang, Xingyuan Xu, Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Immunotherapy 15 (3) (2023)
Enliang Li, Jian Xu, Qi Chen, Xiaozhen Zhang, Xingyuan Xu, Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Immunotherapy (2023)
Enliang Li, Jian Xu, Qi Chen, Xiaozhen Zhang, Xingyuan Xu, Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Immunotherapy 15 (3) (2023)
Kangning Zhang, Xingyuan Xu, Muhammad Asghar Pasha, Christian W Siebel, Angelica Costello, Angela Haczku, Katherine MacNamara, Tingbo Liang, Jinfang Zhu, Avinash Bhandoola, Ivan P Maillard, Qi Yang
Cutting Edge: Notch Signaling Promotes the Plasticity of Group-2 Innate Lymphoid Cells. Journal of immunology (Baltimore, Md. : 1950) 198 (5) (2017)